期刊文献+

细胞保护剂氨磷汀 被引量:5

下载PDF
导出
作者 杨莉 耿宝琴
出处 《实用肿瘤杂志》 CAS 北大核心 2001年第3期213-215,共3页 Journal of Practical Oncology
  • 相关文献

参考文献12

  • 1[1]Capizzi RL. Amifostine:the preclinical basis for broadspectrum selective cytoprotection of normal tissue from cytotoxic therapies [J]. Semin Oncol, 1996,23 (4supple 8):2-17.
  • 2[2]Shuchter LM. Guidelines for the administration of amifostine [J]. Semin Oncol, 1996,23 (4 supple 8) : 40 -43.
  • 3[3]Capizzi RL. The preclinical basis for broad-spectrum selective cytoprotect-ion of normal tissues form cytotoxic therapies by amifostine [J]. Semin Oncol, 1999,26(2 supple 7) :3-21.
  • 4[4]Shaw LM,Bonner H,Lieberman R. Pharmacokinetic profile amifostine [J]. Seminal Oncol, 1996,23 (4 supple 8):18-22.
  • 5[5]Thomas Budd G. Amifostine and chemotherapy-relatedthrombocytoperia [J ]. Semin Oncol, 1996, 23 (4supple 8) :49-52.
  • 6[6]Spencer CM ,Goa KL. Amifostine :a review of its pharmocodynamic and pharmokinetic properties ,and therapeutic potential as a radioprotector and cytotoxic chemoprotector [J]. Drug, 1995,50(6): 1001 - 1031.
  • 7[7]Kemp G,Rose P,Lurain J,et al. Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer [J]. J Clin Oncol, 1996,14 : 2101 - 2112.
  • 8[8]Bohuslavizki KH,Brennar W,Klutmann S,et al. Radioprotection of salivary glands by amifostine in highdose radioiodine therapy[J]. J Nul Med, 1998,39 (7):1237-1242.
  • 9[9]Buntzel J,Kuttnerk,Forhlich D,et al. Selective cytoprotection with amifostine in concurrent radiochemotherapy for head nd neck cancer[J]. Ann Oncol,1998,9(5) :505- 509.
  • 10[10]Rose PG. Amifostine cytoprotection chemothe-rapy for advanced ovarian carcinoma [J]. Semi Oncol,1996,23(4 supple 8) :83-89.

同被引文献62

  • 1管忠震,徐瑞华.奈达铂临床研究进展[J].中国肿瘤临床,2004,31(13):774-780. 被引量:176
  • 2李文钧,郑永兴.石墨炉原子吸收法测定体内顺铂[J].药物分析杂志,1989,9(2):82-85. 被引量:10
  • 3姜秋颖,路丹,信涛.氨磷汀的细胞保护作用对肿瘤化疗病人生活质量的改善[J].哈尔滨医科大学学报,2005,39(5):441-442. 被引量:5
  • 4Grothey A, Goldberg RM.A review of oxaliplatin and its clinical use in colorectal cancer[J] .Expert Opin Pharmacother, 2004,5(10) : 2 159.
  • 5Miyagi Y, Kawanishi K, Miyagi Y, et al .Cytocidal effect and DNA damage of nedaplatin:a mathematical model and analysis of experimental data[J] .Cancer Chem Pharmacol, 2001,47(3) : 229.
  • 6McKeage MJ .Lobaplatin: a new antitumour platinum drug[J]. Expert Opin Investig Drugs, 2001,10(1) : 119.
  • 7Kim DK, Kim HT, Cho YB, et al .Antitumor activity of cis-malonato[ (4R, 5R)-4,5-bis(aminomethyl)-2-isopropyl-1,3-dioxolane] platinum(Ⅱ),a new platinum analogue,as an anticancer agent[J]. Cancer Chem Pharmacol, 1995,35(5) : 441.
  • 8Min Y J, Bang SJ, Shin JW, et al . Combination chemotherapy with 5 - fluorouracil and heptaplatin as first- line treatment in patients with advanced gastric cancer[J] .J Korean Med Sci, 2004,19(3) :3 693.
  • 9Kelland LR. An update on satraplatin: the first orally available platinum anticancer drug[J] .Expert Opin Investig Drugs, 2000,9(6):1 373.
  • 10Kurata T, Tamura T, Sasaki Y, et al .Pharmacokinetic and pharmacodynamic analysis of bis - acetato - ammine - dichloro - cyclohexylamine - platinum( Ⅳ )(JM216) administered once a day for five consecutive days: a phase I study[J] .Jpn J Clin Oncol ,2000,30(9) :377.

引证文献5

二级引证文献24

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部